Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)

Abraham, B., Eksteen, B., Nedd, K., Kale, H., Patel, D., Stephens, J., Shelbaya, A., Chambers, R., & Soonasra, A. (2022). Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Advances in Therapy, 39(5), 2109–2127. https://doi.org/10.1007/s12325-022-02104-6
Authors:
Bincy Abraham
Bertus Eksteen
Khan Nedd
Hrishikesh Kale
Dipen Patel
Jennifer Stephens
Ahmed Shelbaya
Richard Chambers
Arif Soonasra
Affiliated Authors:
Ahmed Shelbaya
Columbia Affiliation:
Subjects:
Biosimilar Pharmaceuticals (MeSH)
Colitis, Ulcerative (MeSH)
Crohn Disease (MeSH)
Inflammatory Bowel Diseases (MeSH)
Author Keywords:
biosimilars
exploratory treatment effectiveness study
inflammatory bowel disease
infliximab
real-world outcomes
elink
Publication Type:
Article
Unique ID:
10.1007/s12325-022-02104-6
PMID:
35296993
DOI:
10.1007/s12325-022-02104-6
Journal:
Advances in Therapy
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record
View PubMed Record
View Web of Science Record

Record Created: